Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases

Elsevier

Available online 10 January 2022

Drug Discovery TodayHighlights•

The clinical application of siRNA for brain disease therapy remains a significant challenge for several reasons.

The siRNA based gene silencing technology has demonstrated significant potential for the treatment of neurodegenerative diseases (NDs).

Nanocarriers can provide promising opportunities for improving neurodegenerative diseases.

In this review we highlight the role of different forms of nanocarriers have been used to treat NDs throw a heavy burden on society.

Abstract

Neurodegenerative disorders (NDs) lead to the progressive degeneration of the structural and physiological functions of the central and peripheral nervous systems, resulting in lifelong cognitive and motor dysfunction. Although comprehensive treatment of NDs is lacking, small interfering (si)RNA has shown therapeutic utility in the form of cellular nuclease-driven downregulation of mRNA levels. Various nanotechnologies have been used to modulate crucial physicochemical and biopharmaceutical properties of siRNA to provide protection and to enhance biomembrane interactions, residence times, tissue absorption, and cellular internalization for improved cytoplasm and/or nucleus interactions. In this review, we highlight advances in, and the role of, siRNA-based nanocarriers for the treatment of various NDs.

Keywords

neurodegenerative disorders

small interfering RNA

nanoparticles

nanostructured lipid carriers

solid lipid nanoparticle

liposomes

View full text

© 2022 Elsevier Ltd. All rights reserved.

留言 (0)

沒有登入
gif